Results 211 to 220 of about 252,165 (283)

Multi-proteomic analyses provide evidence for origin of a co-existing serum monoclonal gammopathy in CLL/MBL [PDF]

Uday Aditya Sarkar, Dylan Nicholas Tabang, Cliodna McNulty, Sabine Allam, Ayazhan Umutbayeva, Stacey M. Fernandes, Mariia Mikhaleva, Roberta S. Azevedo, Zainab Wurie, Ava Bidgoli, Natalie Onofri, J.E. Flinn, Kiyomi Mashima, Ingrid Lourme, Elisavet Vlachonikola, Binu K. Sasi, Paulina Predko, Andreas Agathangelidis, Kenneth C. Parker, Κώστας Σταματόπουλος, Irene M. Ghobrial, Jennifer R. Brown, Hanno Steen, Paolo Ghia   +23 more
openalex   +1 more source

BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells [PDF]

, 2008
Anna Guarini, Sabina Chiaretti, Simona Tavolaro, Roberta Maggio, Nadia Peragine, Franca Citarella, Maria Rosaria Ricciardi, Simona Santangelo, M Marinelli, Maria Stefania De Propris, Monica Messina, Francesca Romana Mauro, Ilaria Del Giudice, Robert Foà   +13 more
openalex   +1 more source

Rod‐Like Cytoplasmic Inclusions in the Peripheral Blood Smear of a Patient with Chronic Lymphocytic Leukemia

eJHaem, Volume 7, Issue 1, February 2026.
Abhishek Prasad, Tran B. Nguyen, Luis F. Carrillo   +2 more
wiley   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, Volume 158, Issue 2, Page 342-356, 15 January 2026.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL. [PDF]

Blood Adv
Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais-Rodrigues C, Besikli-Dimou S, Cerutti A, Doubek M, Enggaard L, Espinet B, Ferrer-Lores B, Garcia Vela JA, Gentile M, Vázquez EG, Gutwein O, Herishanu Y, Jablonowska-Babij P, Jaksic O, Josefsson P, Kalicińska E, Kislova M, Lista E, Kotsianidis I, Marquet J, Martino EA, McAuley C, Mela Osorio MJ, Moia R, Mosquera C, Nikitin E, Pavlovsky MA, Pfister V, Savaş EM, Scarfò L, Sever M, Shvidel L, Simkovic M, Stavroyianni N, Talimtzi P, Tranidou A, Visentin A, Vrachiolias G, Wasik-Szczepanek E, Wróbel T, Yağcı M, Cellini A, Chatzidimitriou A, Gaidano G, Anderson MA, Davids MS, Brown JR, Niemann CU, Stamatopoulos K, Ghia P, Ahn IE, Koren-Michowitz M.   +56 more
europepmc   +1 more source

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study [PDF]

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, Persefoni Talimtzi, Maria K. Angelopoulou, Tomáš Arpáš, Laura Ballotta, Leonidas Benetatos, Alessandro Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria Del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Anna Maria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Virginia Iancu, Vanessa Innao, Krzysztof Jamroziak, Elżbieta Kalicińska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Arturo Pavlovsky, Sara Pepe, Ernesto Pérez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina P. Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vázquez, Candida Vitale, Mohamed A. Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Κώστας Σταματόπουλος, Paolo Ghia   +67 more
openalex   +1 more source

Chronic Lymphocytic Leukemia (CLL): First-Line Treatment [PDF]

, 2005
Michael Hallek, On Behalf Of The German CLL Study Group   +1 more
openalex   +1 more source

Accelerated Chronic Lymphocytic Leukaemia Complicated by Bilateral Pathological Humeral Fractures

eJHaem, Volume 7, Issue 1, February 2026.
Mariyum Khawar, Varvara Bashkirova, Vidhya Manohar, Jaymathi Dhanapal   +3 more
wiley   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, Volume 158, Issue 2, Page 423-432, 15 January 2026.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source